CareDx, Inc. is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Brisbane, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $380 million and a loss of $21 million (its filed statements).
Usage businessServices-Medical LaboratoriesBrisbane, CAfilings since 20039 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.3 out of ten, 9 of 9 metrics filed: past 4.8 out of ten, present 5.3 out of ten, future 5.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 2.0 out of ten. 5 warning events since 2017; the latest 2018-04-16. 20th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.0 out of ten. +28.2% a year over 10 filed years; profitable in 1 of 10. 50th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 8.7 out of ten. Share count steady. 100% of cash flow returned. Insiders: 26 sales, 0 purchases. 87th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.4 out of ten. ROE -7%: lost 7¢ per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar. 74th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.7 out of ten. top 43% of 23 in its family; net margin -5.6%. 57th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 1.6 out of ten. bottom 16% of 17 in its family for leadership; chief executive since 2024. 16th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 6.2 out of ten. top 38% of 23 in its family for room to expand. 62nd percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.2 out of ten. bottom 42% of 23 in its family for growth drivers. 42nd percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 20 in its family for expectations against reality. 69th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-30 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 2003. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Service 72%, Patient and Digital Solutions 15%, Product 13%. By geography: United States 95%, Outside the United States 5%. As tagged in its annual report (Form 10-K, filed 2026-02-25).
Who runs it
Hanna, John Walter Jr (President and CEO); Maag, Peter (Executive Chair); Kennedy, Keith (CFO & COO); Smith, Nathan (Chief Financial Officer); Jain, Abhishek (Chief Financial Officer); Meng, Jessica (Chief Commercial Officer); Novack, Jeffrey Adam (Secretary and General Counsel); Goldberg, Michael (director); Bickerstaff, George (director); Cournoyer, Christine (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.